EDUCATING LEADERS IN PHARMACY AND PHARMACEUTICAL SCIENCES SINCE 1886
Sathy V. Balu-Iyer PhD
Sathy V. Balu-Iyer
PhD
Professional Summary:
Research interest is in the area of protein delivery and immunotherapy.
Current research projects:
1. Development of lipidic nano particle containing therapeutic proteins and is supported by NHLBI/NIH. The overall goal of the project is to improve therapeutic efficacy of protein based therapies for bleeding and lysosomal disorders using a multidisciplinary approach involving Biophysics/Bioengineering, immunology and pharmacokinetics/Pharmacodynamics.
2. Re-activating Memory T Cells in the Microenvironment of Human Tumors and development of in situ vaccination. This project is supported by NCI/NIH (Dr. Bankert, PI, Balu-Iyer Co-PI). Our aim is to to rationally develop therapeutic intervention by understanding the molecular mechanism of TCR arrest.
3. Develop novel strategies to treat food allergies and autoimmune conditions using the tolerogenic properties of biomolecules.
4. Formulation and delivery of Monoclonal antibody based products: Understand and develop strategies to improve efficacy of antibody based therapeutics particularly given via sc route of administration
Education and Training:
- PhD, Indian Institute of Science (1993)
- MS/BA, Madurai Kamaraj University, India (1987)
- Postdoctoral Fellow, Pharmaceutical Sciences - drug delivery, SUNY - University at Buffalo
Employment:
- Professor (2012-present)
- Adjunct Faculty (2000-present)
- Associate Director (2000-present)
- Associate Professor (2006–2012)
- Assistant Professor (2000–2006)
- Assistant Professor (2000)
- Research Assistant Professor (1997–2000)
- Post Doctoral Associate (1993–1996)
- Post Doctoral Associate (1993)
Awards and Honors:
- Fellow American Association of Pharmaceutical Sciences (2015)
- Visionary Innovator Award (2015)
- Innovation in Biotechnology Award (2012)
- Exceptional Scholar Teaching Innovation Award (2011)
- Inventor of the Year award 2011 (2011)
- Nominated for Inventor of the year 2010 (2010)
- Outstanding Reviewer - 2009 (2009)
- Member, Editorial Board (2006)
- Teacher of the Year Award (2006)
- Reviewer Abstracts for poster and podium presentations (2005)
- Guest Editor (2005)
- Reviewer North Carolina Biotechnology Center Institutional Development (2004)
- Reviewer Cooperative Grants Program (2003)
- Mail reviewer (2003)
- Inventor of the Year Award (2002)
- First Patent Award (2002)
Research Expertise:
- Immunotherapy: Develop lipid mediated tolerance strategies to overcome unwanted immune responses (protein and antibody therapeutics, allergies, autoimmune conditions and gene therapy)
- Protein delivery and immunotherapy: Adopts an interdisciplinary approach of biophysics/bioengineering, pharmacokinetic and pharmacodynamic and immunology.
- Protein formulation: Physicochemical and analytical methods of assessing protein structure, function, and stability in developing improved dosage forms.
Grants and Sponsored Research:
- June 2022–May 2027
Lipid mediated oral tolerance
NIH/NIAID
Role: Co-Principal Investigator
$2,327,530 - February 2002–December 2019
Development and pharmacology of novel lipidic rAHF and Biotherapeutics
NHLBI
Role: Principal Investigator
$1,000,000 - June 2016–June 2018
Investigation of formulation variables on sc bioavailability of monoclonal antibody therapeutics
Role: Principal Investigator
$148,000 - July 2005–June 2006
Product Development Fund
University at Buffalo
Role: Co-Principal Investigator
$33,000
Patents:
- Composition for less immunogenic and long circulating Protein-Lipid complex (2011)
- Method for treating coagulation disorders (2011)
- Method of complexing a protein by the use of a dispersed system and protein Type: Regular (2010)
- Composition and method of preparation of micro particulate IL-12 (2010)
- RECONSTITUTION MEDIUM FOR PROTEIN AND PEPTIDE FORMULATIONS Docket Number: 5847 Type: Other Other Type: Divisional (2008)
- Compositions of less immunogenic and long circulating protein-lipid complex Type: Regular (2007)
- Method for treating blood coagulation disorders Type: Regular (2007)
- COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: Europe (2007)
- COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: Canada (2007)
- Composition and method of preparation of liposomal microparticulate IL-12 f Type: Regular (2006)
- RECONSTITUTION MEDIUM FOR PROTEIN AND PEPTIDE FORMULATIONS Docket Number: 5847 Type: Other Other Type: Europe (2006)
- COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: PCT (2006)
- RECONSTITUTION MEDIUM FOR PROTEIN AND PEPTIDE FORMULATIONS Docket Number: 5847 Type: Other Other Type: Canada (2006)
- COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: Continuation-in-Part (2005)
- Method and composition of pegylated phosphoserine complex (2005)
- RECONSTITUTION MEDIUM FOR PROTEIN AND PEPTIDE FORMULATIONS Docket Number: 5847 Type: Regular (2004)
- RECONSTITUTION MEDIUM FOR PROTEIN AND PEPTIDE FORMULATIONS Docket Number: 5847 Type: Other Other Type: PCT (2004)
- COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Regular (2004)
- COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: PCT (2004)
- COMPOSITION OF THE RECONSTITUTIONAL MEDIUM FOR PROTEIN AND PEPTIDE FORMULAT Docket Number: 5847 Type: Provisional (2003)
- METHOD FOR PREPARING PROTEIN-LIPID COMPLEXES WITH LOW IMMUNOGENICITY Docket Number: 5785 Type: Provisional (2003)
- Stabilization of Taxane formulations (2002)
- METHOD AND APPARATUS FOR HEATING AND CONTROLLING THE TEMPERATURE OF ULTRA S Docket Number: 0330 Type: Regular (1986)
- COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: Japan
- COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: Australia
- COMPOSITIONS AND METHODS FOR LESS IMMUNOGENIC PROTEIN FORMULATIONS Docket Number: 5785 Type: Other Other Type: New Zealand
Journal Articles:
- Gaitonde P; Ramakrishnan R; Chin J; Kelleher R; Bankert R; Balu-Iyer SV. Exposure to Factor VIII in the presence of Phosphatidylserine induces hyporesponsiveness to Factor VIII challenge in Hemophilia A mice. Journal of Biological Chemistry. 2013; 288.
- K. A. Shetty, E. P. Merricks, R. Raymer, N. Rigsbee, T.C. Nichols and Balu-Iyer SV. Soy phosphatidylinositol containing lipid nanoparticle prolongs the plasma survival and hemostatic efficacy of B-domain deleted recombinant canine Factor VIII in Hemophilia A dogs. J Pharm Sci. 2016; 105(10).
- Schneider JL, Balu-Iyer SV. Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease. J Pharm Sci. 2016; 105(10).
- Ramakrishnan R, Balu-Iyer SV. Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model. J Pharm Sci. 2016; 105(10).
- Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice. Biopharm Drug Dispos. 2016; 37(7).
- Ramakrishnan R, Davidowitz A, Balu-Iyer SV. Exposure of FVIII in the Presence of Phosphatidyl Serine Reduces Generation of Memory B-Cells and Induces Regulatory T-Cell-Mediated Hyporesponsiveness in Hemophilia A Mice. J Pharm Sci. 2015; 104(8).
- Fathallah AM, Turner MR, Mager DE, Balu-Iyer SV. Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. Biopharm Drug Dispos. 2015; 36(2).
- Fathallah AM, Balu-Iyer SV. Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics. J Pharm Sci. 2015; 104(2).
- Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice. J Pharm Sci. 2015; 104(2).
- Fathallah AM, Ramakrishnan R, Balu-Iyer SV. O-phospho-l-serine mediates hyporesponsiveness toward FVIII in hemophilia A-murine model by inducing tolerogenic properties in dendritic cells. J Pharm Sci. 2014; 103(11).
- Gaitonde P, Purohit VS, Balu-Iyer SV. Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein. Eur J Pharm Sci. 2014; 66C.
- Kosloski MP, Shetty KA, Wakabayashi H, Fay PJ, Balu-Iyer SV. Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo. AAPS J. 2014; 16(5).
- Kosloski M; Pisal D; Mager DE; Balu-Iyer SV. Allometry of Factor VIII and informed scaling of next generation therapeutic proteins. Journal of Pharmaceutical Sciences. 2013.
- Trummer BJ, Iyer V, Balu-Iyer SV, O‘Connor R, Straubinger RM. Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib. J Pharm Sci. 2012; 101(8).
- Trummer BJ; Iyer VS; Balu-Iyer SV; O'Connor R; Straubinger RM. Physicochemical properties of EGF receptor inhibitors and development of a nanoliposomal formulation of gefitinib. Journal of Pharmaceutical Sciences. 2012; 101.
- Gaitonde P; Straubinger RM; Bankert R; Balu-Iyer SV. Down-regulation of CD40 signal and induction of TGF- beta by Phosphatidylinositol, mediates reduction in immunogenicity against recombinant human Factor VIII. Journal of Pharmaceutical Sciences. 2012; 101.
- Bhansali SG; Balu-Iyer SV; Morris ME. Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S. J Pharm Sci. 2012; 10.
- Peng A; Ding H; Kosloski M; Balu-Iyer SV. PEGylation of FVIII-PI Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Murine Model. AAPS Journal. 2012; 14.
- Peng A; Doty A; Pisal D; Balu-Iyer SV. Phosphatidylinositol induces fluid phase formation and packing defects in phosphatidylcholine model membranes. Chemistry and Physics of Lipids. 2012; 165.
- Kagan L; Turner M; Balu-Iyer SV; Mager DE. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res. 2012; 29.
- Kosloski M; Peng A; Varma P; Miclea RD; Mager DE; Balu-Iyer SV. Immunogenicity and pharmacokinetic studies of recombinant Factor VIII containing lipid cochleates. Drug Delivery. 2011; 8 (20.
- Gaitonde P; Balu-Iyer SV. In vitro Immunogenicity Risk-assessment of Therapeutic Proteins in Preclinical Setting. Methods in Molecular Biology. 2011; 716 (.
- Peng A; Straubinger RM; Balu-Iyer SV. Phosphatidylinositol containing lipidic particle reduces inhibitor development and catabolism of factor VIII in hemophilia A mice. AAPS Journal. 2011; 12 (2.
- Pisal D; Balu-Iyer SV. Phospholipid binding improves plasma survival of Factor VIII. Thrombosis and Haemostasis. 2011; 104 (.
- Pisal DS; Balu-Iyer SV. Phospholipid Binding Lowers Immunogenicity of Human Recombinant Factor VIII in von Willebrand Factor Knockout Mice. Thrombosis and Haemostasis. 2011; 105.
- Gaitonde P, Balu-Iyer SV. In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting. Methods Mol Biol. 2011; 716.
- Peng A, Straubinger RM, Balu-Iyer SV. Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice. AAPS J. 2010; 12(3).
- Pisal DS, Kosloski MP, Balu-Iyer SV. Delivery of therapeutic proteins. J Pharm Sci. 2010; 99(6).
- Themistou E; Singh I; Shang C; Balu-Iyer SV; Alexandridis P; Neelamegham S. Application of fluorescence spectroscopy to quantify shear-induced protein conformation change. Biophysical Journal. 2010; 97.
- Balu-Iyer SV; Pisal DS; Kosloski M. Delivery of Therapeutic Proteins Journal of Pharmaceutical Sciences. 2010; 99 20.
- Peng A; Gaitonde P; Kosloski MP; Miclea RD; Varma P; Balu-Iyer SV. Effect of route of administration of human recombinant Factor VIII on its immunogenicity in Hemophilia A mice Journal of Pharmaceutical Sciences. 2010; 98 20.
- Kosloski M; Miclea RD; Balu-Iyer SV. Role of Glycosylation in Conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human Factor VIII AAPS Journal. 2010; 11 20.
- Rao G; Iyer V; Kosloski MP; Pisal DS; Midduagh CR; Balu-Iyer SV. Use of a folding model and in situ biophysical techniques rational formulation development and stability testing of monoclonal antibody therapeutics Journal of Pharmaceutical Sciences. 2010; 99 20.
- Rao G; Iyer V; Kosloski MP; Pisal DS; Midduagh CR; Balu-Iyer SV. Use of a folding model and in situ biophysical techniques rational formulation development and stability testing of monoclonal antibody therapeutics Journal of Pharmaceutical Sciences. 2010; 99 20.
- Rao G, Iyer V, Kosloski MP, Pisal DS, Shin E, Middaugh CR, Balu-Iyer SV. Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics. J Pharm Sci. 2010; 99(4).
- Peng A, Gaitonde P, Kosloski MP, Miclea RD, Varma P, Balu-Iyer SV. Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice. J Pharm Sci. 2009; 98(12).
- Themistou E, Singh I, Shang C, Balu-Iyer SV, Alexandridis P, Neelamegham S. Application of fluorescence spectroscopy to quantify shear-induced protein conformation change. Biophys J. 2009; 97(9).
- Kosloski MP, Miclea RD, Balu-Iyer SV. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J. 2009; 11(3).
- Korotchkina LG; Ramani K; Balu-Iyer SV. Folding consideration of therapeutic proteins. Prog Mol Biol Transi Sci. 2008; 83.
- Ramani K; Miclea RD; Gaitonde P; Straubinger RM; Balu-Iyer SV. Passive Transfer of Polyethyleneglycol to Liposomal-Recombinant Human FVIII Enhances its Efficacy in a Murine Model for Hemophilia A. Journal of Pharmaceutical Sciences. 2008; 97.
- Themistou E; Singh I; Balu-Iyer SV; Alexandridis P; Neelamegham S. Change in Solution Structure of Human Blood Protein von Willebrand Factor Caused by Shear. Polym. Prepr. (Am. Chem. Soc., Div. Polym. Chem.). 2008; 49.
- Ramani K; Miclea RD; Purohit VS; Straubinger RM; Mager DE; Balu-Iyer SV. Phosphatidylserine Containing Liposomes reduce Immunogenicity of Recombinant Human Factor VIII in a Murine Model of Hemophilia A. Journal. Pharmaceutical Sciences. 2008; 97.
- Korotchkina LG, Ramani K, Balu-Iyer SV. Folding considerations for therapeutic protein formulations. Prog Mol Biol Transl Sci. 2008; 83.
- Miclea RD, Varma PR, Peng A, Balu-Iyer SV. Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochim Biophys Acta. 2007; 1768(11).
- Miclea RD; Varma PR; Peng A; Balu-Iyer SV. Development and characterization of lipidic cochleate containing recombinant factor VIII. Biochimica Biophysica Acta. 2007; 1768.
- Miclea RD, Purohit VS, Balu-Iyer SV. O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII. AAPS J. 2007; 9(2).
- Miclea RD; Purohit VS; Balu-Iyer SV. O-Phospho-L-Serine, Multi-functional Excipient for B Domain Deleted Recombinant Factor VIII. AAPS. 2007; 9.
- Purohit VS, Balasubramanian SV, Balu-Iyer SV. Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity. AAPS J. 2006; 8(2).
- Purohit VS, Middaugh CR, Balasubramanian SV, Balu-Iyer SV. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J Pharm Sci. 2006; 95(2).
- Purohit VS, Balasubramanian SV, Balu-Iyer SV. Interaction of dicaproyl phosphatidylserine with recombinant factor VIII andits impact on immunogenicity. AAPS J. 2006; 8(2).
- Ramani K, Purohit V, Middaugh CR, Balasubramanian SV, Balu-Iyer SV. Aggregation kinetics of recombinant human FVIII (rFVIII). J Pharm Sci. 2005; 94(9).
- Ramani K, Purohit VS, Miclea RD, Middaugh CR, Balasubramanian SV, Balu-Iyer SV. Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII). J Pharm Sci. 2005; 94(6).
- Purohit VS, Ramani K, Sarkar R, Kazazian HH, Balasubramanian SV, Balu-Iyer SV. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem. 2005; 280(18).
- Campbell RB, Balasubramanian SV, Straubinger RM, Balu-Iyer SV. Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. J Pharm Sci. 2001; 90(8).
- Campbell RB, Balasubramanian SV, Straubinger RM, Balu-Iyer SV. Phospholipid-cationic lipid interactions: influences on membrane and vesicle properties. Biochim Biophys Acta. 2001; 1512(1).
- Situ H, Balasubramanian SV, Bobek LA. Role of alpha-helical conformation of histatin-5 in candidacidal activity examined by proline variants.. Biochim Biophys Acta. 2000; 1475(3).
- Zhou R, Balasubramanian SV, Kahl SB, Straubinger RM. Biopharmaceutics of boronated radiosensitizers: liposomal formulation of MnBOPP (manganese chelate of 2,4-(alpha, beta-dihydroxyethyl) deuterioporphyrin IX) and comparative toxicity in mice. J Pharm Sci. 1999; 88(9).
- Shao K, Balasubramanian SV, Bahl OP, Balu-Iyer SV. Role of amino acid residues at the interface of alpha52asparginyl-N-glycosyl chain of human choriogonadotropin. Mol Cell Endocrinol. 1999; 150(1-2).
- Shao K, Balasubramanian SV, Pope CM, Bahl OP, Balu-Iyer SV. Effect of individual N-glycosyl chains in the beta-subunit on the conformation of human choriogonadotropin. Mol Cell Endocrinol. 1998; 146(1-2).
- Purohit S, Shao K, Balasubramanian SV, Bahl OP, Balu-Iyer SV. Mutants of human choriogonadotropin lacking N-glycosyl chains in the alpha-subunit. 1. Mechanism for the differential action of the N-linked carbohydrates. Biochemistry. 1997; 36(40).
- Balasubramanian SV, Alderfer JL, Straubinger RM. Solvent- and concentration-dependent molecular interactions of taxol (Paclitaxel). J Pharm Sci. 1994; 83(10).
- Balasubramanian SV, Straubinger RM. Taxol-lipid interactions: taxol-dependent effects on the physical properties of model membranes. Biochemistry. 1994; 33(30).
Professional Memberships:
- American Society for Biochemistry and Molecular Biology (2005)
- American Society for Biochemistry and Molecular Biology; nominated to become a Regular member in the American Society for Biochemistry and Molecular Biology (ASBMB) (2005–present)
- Biophysical Society; Member (2003–present)
- International Society on Thrombosis and Haemostasis; Member (2002–present)
- American Association of Pharmaceutical Scientists (2000)
- American Association of College Pharmacy; Member (2000)
- American Association of Pharmaceutical Scientists; Member (2000–present)
- Biophysical Society; Member (1995–1998)
Presentations:
- "sc delivery of biotherapeutics" Dicerna, Dicerna (2015)
- "Tricks of Modified Release of biologics" AAPS Annual Meeting, AAPS (2015)
- "Role of immunogenicity in biological drug development" Workshop on Pharmacodynamics and Systems Pharmacology, Dublin City University (2014)
- "Protein drugs; Formulation approaches for stabilizing biologics" FIP World congress of Pharmacy and Pharmaceutical Sciences, Dublin, FIP (2013)
- "Reverse Vaccination and subcutaneous route – A novel strategy to mitigate immunogenicity" Abbvie, Abbvie (2013)
- "Immunogenicity and Pharmacokinetics of subcutaneous administered therapeutic proteins" AAPS Biotechnology, AAPS (2013)
- "Immunogenicity and pharmacokinetics of subcutaneously administered therapeutic proteins" AAPS NBC, AAPS, National Biotechnology Conference (2013)
- "Lipid mediated Induction of Immunological Tolerance" Immunogenicity Summit 2012, Cambridge Health Tech (2012)
- "Development of next generation protein therapeutics" NIAC, School of Pharmacy and Pharmaceutical Sciences (2012)
- "Reverse Vaccination Lipid renders protein tolerogenic" AAPS Biotechnology, AAPS (2012)
- "Mitigation of immunogenicity of Factor VIII by lipid mediated tolerance" IIR Annual Meeting, IIR (2012)
- "Immunogenicity of Therapeutic Proteins" IIR Annual Meeting, IIR (2011)
- "The pharmacokinetics and lymphatic exposure of recombinant human vascular endothelial growth factor VEGF-C156S after iv and sc administration" Pharmacology Day, University at Buffalo (2010)
- "Phosphatidylserine and immune regulation to protein therapeutics" 11th annual immunogenicity for biotherapeutics, IIR USA (2010)
- "(1) Multifunctional formulation approaches to reduce immunogenicity of protein therapeutics" New Jersey Pharmaceutical Association of Science and Technology, New Jersey Pharmaceutical Association of Science and Technology (2010)
- "(2) Rational mechanism based formulation development to overcome Immunogenicity" Cambridge Health Tech PEP talk, Cambridge Heath Institute (2010)
- "Immunogenicity of FVIII, a rational mechanism based formulation development" Protein stability conference, University of Colorado (2009)
- "Development of lipidic recombinant Factor VIII to improve safety and efficacy of replacement therapy" Wyeth Andover (2009)
- "Development and pharmacokinetic evaluation of liposomal VEGF-C156S." Great Lakes Symposium (2008)
- "Formulation and biophysical characterization of liposomes encapsulating VEGF-C156S for PK/PD studies." Sigma Xi Research Conference (2008)
- "Formulation and biophysical characterization of liposomes encapsulating VEGF-C156S for PK/PD studies." UB-Pfizer Conference (2008)
Service Activities:
- Grant Reviewer; STW - Netherlands; Other (2010)
- Organizing committee, Symposium nano for Medicine; Organize a national symposium on nanomedicine; Member (2009)
- Department of Pharmaceutical Sciences Admissions committee; Member (2007–2019)
- Life Sciences IRDF; Reviewer (2007)
- Center for Protein Therapeutics; Member (2007)
- Integrated NanoMedicine Search committee - Biological Sciences; Member (2007)
- Integrated NanoMedicine Search committee; Member (2006)
- Life Sciences Panel IRDF; To review proposals submitted for IRDF; Reviewer (2004)
- UB2020 Integrated nano structures -chemical engineering; One of the author of the UB2020 integrated nano structures; Member (2003)
- Curriculum committee; Member (2002)
- Pharmaceutical Instrumentation Facility; Oversee pharmaceutical sciences Instrumentation facility, participate as Co I in shared equipment grants, train users managing the facility and trained users that have contributed to over 100 publication in peer reviewed journals, participated in several; Other (2000)
- Pharmaceutical Sciences Instrumentation Facility; To oversee pharmaceutical instrumentation facility, participate in shared equipment proposal writing, train new users Successfully managing this instrumentation facility over several years that have contributed to over 100 peer-reviewed journal article,; Other (2000)
- SOPPS Safety committe; Member (2000)
- Accreditation Facilities sub-committe; Member
- Author, UB2020 Integrated nano systems, white paper; Other
- Committee; Therapeutic Protein Immunogenicity Focus GroupAAPS; Other
- Course Reviewer; American Association of Pharmaceutical Scientists; Other
- Distinguished speaking faculty; Cambridge Health Tech; Other
- Distinguished speaking faculty; Institute for International Research; Other
- Editorial Board; Asian Chemical Letters - Editorial Board; Other
- Editorial Advisory Board; International Journal of Clinical research and Drug Development - Editorial Advisory Board; Other
- Editorial advisory Board; Journal of Pharmaceutical Sciences - Editorial advisory Board; Other
- Editorial advisory Board; Recent Patents on Endocrine, Metabolic & Immune Drug Discovery - Editorial advisory Board; Other
- Faculty advisory committee, Integrated nano systems strategic strength; Member
- Faculty Search Committee; Member
- Graduate Student Admissions committee; Member
- Graduate Student Admissions sub-committee; Member
- Grant Reviewer; Israel Science Foundation; Other
- Incubator and start-up committe; Member
- Instrumentation Facility; Other
- Member; American Association of Pharmaceutical Scientists; Other
- Member; American Society for Biochemistry and Molecular Biology; Other
- Participant, iHUB; Innovation HUB (iHUB), Science and Technology Transfer and Economic Outreach, University at Buffalo. iHUB is a federal grant awarded to UB from Economic Development Administration (EDA) to foster innovation, job creation and private capital investment in; Other
- Pharm D faculty advisor; Academic advising for Pharm D students (3-4 students per year and total of 12-16 students); Other
- Reviewer; Trinity College Ireland; Other
- Reviewer/Presenter; Biotechnolgy 101 AAPS; Other
- Undergraduate affairs committee; Member